Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


The Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) was a multi-centre, randomised, double-blind, parallel-group, pragmatic,  primary prevention trial comparing the effect of slow-release metformin with placebo on a macrovascular composite outcome in people in primary care with non-diabetic hyperglycaemia and at high cardiovascular risk. Participants were allocated randomly to treatment with either metformin XR or placebo, and were followed for 5-7 years.

GLINT was run jointly by the University of Cambridge MRC Epidemiology Unit, the University of Oxford Diabetes Trials Unit (DTU) and the Leicester Diabetes Centre.  The joint trial Sponsors were the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The feasibility phase of GLINT was funded by the NIHR Health Technology Assessment (HTA) programme.

The GLINT feasibility phase of 500 individuals ran from 2015-2017 with a plan to expand in the main trial to approximately 12,900 UK participants.

The results are available here.


Joint chairs

Angelyn Bethel
Nicholas Wareham

Chief adviser

Rury Holman

Chief investigator

Simon Griffin


NIHR Health Technology Assessment (HTA) programme

Reference number